GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 370 Shares

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 370 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $71.26, for a total value of $26,366.20. Following the completion of the transaction, the chief financial officer now directly owns 4,105 shares in the company, valued at approximately $292,522.30. The trade was a 8.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, April 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $113.09, for a total value of $43,878.92.
• On Wednesday, April 9th, Kevin Feeley sold 15,516 shares of GeneDx stock. The shares were sold at an average price of $92.18, for a total value of $1,430,264.88.
• On Wednesday, March 26th, Kevin Feeley sold 8,746 shares of GeneDx stock. The shares were sold at an average price of $95.61, for a total value of $836,205.06.
• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total value of $87,331.84.

GeneDx Stock Performance

Shares of NASDAQ:WGS traded down $3.21 on Thursday, hitting $69.18. The company's stock had a trading volume of 817,796 shares, compared to its average volume of 772,465. GeneDx Holdings Corp. has a 12 month low of $23.88 and a 12 month high of $117.75. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -35.30 and a beta of 1.96. The stock's 50-day moving average is $80.52 and its two-hundred day moving average is $82.12. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.17. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $87.12 million during the quarter, compared to analysts' expectations of $79.90 million. On average, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on WGS. Wells Fargo & Company lowered their price target on GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. The Goldman Sachs Group upped their price objective on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Jefferies Financial Group upgraded GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research note on Friday, May 9th. Guggenheim started coverage on GeneDx in a research note on Thursday, May 15th. They set a "buy" rating and a $88.00 price objective for the company. Finally, TD Securities lowered their price objective on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, GeneDx presently has a consensus rating of "Moderate Buy" and a consensus price target of $86.75.

Institutional Trading of GeneDx

Institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in shares of GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after buying an additional 316 shares during the period. Global Retirement Partners LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at $28,000. GAMMA Investing LLC lifted its holdings in shares of GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after purchasing an additional 264 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of GeneDx during the fourth quarter valued at $35,000. Finally, US Bancorp DE lifted its holdings in shares of GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after purchasing an additional 548 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.